The Effect and Mechanism of Oleanolic Acid in the Treatment of Metabolic Syndrome and Related Cardiovascular Diseases

• Published in: Molecules (Basel, Switzerland) Vol. 29; no. 4; p. 758
• Main Authors: Luo, Quanye, Wei, Yu, Lv, Xuzhen, Chen, Wen, Yang, Dongmei, Tuo, Qinhui
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.02.2024; MDPI
• Subjects: Adipocytes; Blood pressure; cardiovascular diseases; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - etiology; Cholesterol; Diabetes; Diuretics; Fatty acids; Glucose; Health aspects; Homeostasis; Humans; Hydrochlorothiazide; Hyperglycemia; Hyperlipidemia; Hypertension; Inflammation; Insulin resistance; Kinases; Lipids; Liver; Mediation; Metabolic Diseases; Metabolic disorders; Metabolic syndrome; Metabolic Syndrome - drug therapy; Metabolites; Obesity; oleanolic acid; Oleanolic Acid - pharmacology; Oleanolic Acid - therapeutic use; Oxidative stress; Proteins; Review; Sterols; Transcription factors; Tumor necrosis factor-TNF; metabolic syndrome; oleanolic acid; cardiovascular diseases
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules29040758

Metabolic syndromes (MetS) and related cardiovascular diseases (CVDs) pose a serious threat to human health. MetS are metabolic disorders characterized by obesity, dyslipidemia, and hypertension, which increase the risk of CVDs' initiation and development. Although there are many availabile drugs for treating MetS and related CVDs, some side effects also occur. Considering the low-level side effects, many natural products have been tried to treat MetS and CVDs. A five-cyclic triterpenoid natural product, oleanolic acid (OA), has been reported to have many pharmacologic actions such as anti-hypertension, anti-hyperlipidemia, and liver protection. OA has specific advantages in the treatment of MetS and CVDs. OA achieves therapeutic effects through a variety of pathways, attracting great interest and playing a vital role in the treatment of MetS and CVDs. Consequently, in this article, we aim to review the pharmacological actions and potential mechanisms of OA in treating MetS and related CVDs.